Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Amgen Strikes Early-Access Deal In England For Lung Cancer Drug Lumakras

Patients To Start Receiving The Drug In The Next Few Weeks

Executive Summary

Patients in England with non-small cell lung cancer will be the first In Europe to be offered Amgen’s KRAS G12C inhibitor.

You may also be interested in...



Pricing Deals Spell Good News For Exkivity & Vimizin In England

Access to Takeda’s lung cancer drug, Exkivity, is being fast-tracked, and BioMarin’s Vimizin, for mucopolysaccharidosis type 4A, is switching to routine use after what the MPS Society called “a long and at times difficult journey.”

Tens Of Thousands To Benefit From English Funding Nod For siRNA Cholesterol Drug Leqvio

A landmark population-level agreement between Novartis and the National Health Service for the gene silencing therapy Leqvio is now being implemented following the thumbs up from health technology assessment body NICE.

Keeping Track: US FDA Approves Amgen’s Lumakras, Myovant’s Myfembree; New Claims For Biohaven’s Nurtec, BMS’ Zeposia

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS144925

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel